Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat… Ended

2023-507698-16-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-10-14
Clinical study of acalabrutinib and tafasitamab in previously treated marginal zone lymphoma Ended

2024-514122-23-00 Marginal Zone Lymphomas refractory to or in first or gr 4 2021-10-07
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended

2023-508838-33-00 Chronic Myeloid Leukemia 5 2021-10-06
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro… Ended

2024-510812-64-00 Well-differentiated Aggressive Grade 2 and Grade 3, Som 5 2021-09-30
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Breast Cancer 5 2021-09-30
MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex… Ended

2023-509208-14-00 MULTIPLE MYELOMA 5 2021-09-28
A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET Ended

2023-508723-12-00 gastroenteropancreatic neuroendocrine tumors 5 2021-09-27
Phase 3 Randomized Study of Talazoparib with Enzalutamide in Men with DDR Gene Mutated mCSPC Ended

2024-510809-28-00 Metastatic Castration-sensitive Prostate Cancer 5 2021-09-27
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combina… Ended

2023-510307-22-00 Advanced head and neck cancer 1 2021-09-24
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lun… Ended

2023-507494-18-00 Non-small cell lung cancer with ROS proto-oncogene 1, r 5 2021-09-24
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung… Ended

2024-513770-22-00 Malignant Solid Tumors - Non Small Cell Lung Cancer 4 2021-09-22
An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic… Ended

2024-514905-79-00 Metastatic pancreatic ductal adenocarcinoma 9 2021-09-17
A trial for relapsed Multiple Myeloma patients (Isatuximab-dexamethasone) Ended

2024-513397-21-00 Relapsed Multiple Myeloma 4 2021-09-16
The STARBOARD Study: Phase 3 Study of Encorafenib and Binimetinib Plus Pembrolizumab in BRAF V600E/K Mutation-Positive Metastatic or Unresec… Ended

2024-512038-13-00 Metastatic or unresectable locally advanced BRAF V600E/ 5 2021-09-16
A study investigating what potential benefits adding AZD2811 might have to the current standard of care maintenance therapy of durvalumab in… Ended

2024-511887-10-00 First-line patients with extensive disease small-cell l 4 2021-09-14
A trial to learn how safe rilvegostomig (AZD2936) is, how it moves throughout the body over time, and how well it works in adults with advan… Ended

2023-508262-15-00 Advanced Non-small Cell Lung Cancer, Metastatic Non-sma 7 2021-09-09
Phase 1 / 2 Study Evaluating MCLA-129 in Advanced NSCLC Ended

2024-514461-19-00 Solid Tumors 9 2021-09-09
A Phase 2 Study of Avutometinib (VS-6766) Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAM… Ended

2024-516986-35-00 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) 4 2021-09-06
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended

2023-508194-89-00 Persistent or Recurrent Rare Epithelial Ovarian Tumors 4 2021-08-30
A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended

2023-507687-38-00 Participants with extensive-stage small cell lung cance 9 2021-08-23
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended

2023-503905-12-00 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duc 4 2021-08-20
A Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With MM Who Are Refractory to at Least One PI, One IMiD and One Ant… Ended

2023-504479-25-00 Multiple myeloma 4 2021-08-20
Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended

2023-507963-20-00 Metastatic Gastric Adenocarcinoma 5 2021-08-19